BRF (BRFS3) Q4 2025 earnings summary

Executive summary

• Achieved highest volume and revenue since the consolidation of BRF in 2022, driven by a diversified multi-protein platform and strong brands.

• Net revenue reached R$163,963 million in 2025, up 11.9% year-over-year, with significant growth in processed products and expansion into new markets and product lines.

• Operational efficiency improved through corporate structure optimization and supply chain initiatives, capturing R$1bn in savings in 2025.

• Domestic market volumes grew 7.2% year-over-year, while external market volumes rose 1.0%, despite export restrictions and avian influenza impacts.

• Strategic investments and new export authorizations supported international expansion, including a return to the EU market and new facilities in the Middle East and China.

Financial highlights

• Net revenue reached R$163,963 million in 2025, up 11.9% year-over-year; 4Q25 net revenue was R$43,915 million, up 4.8% from 4Q24.

• Adjusted EBITDA for 2025 was R$13,036 million, down from R$13,584 million in 2024; 4Q25 Adjusted EBITDA was R$3,410 million, down from R$3,750 million in 4Q24.

• Net income for 2025 was R$358 million, a significant decrease from R$1,619 million in 2024; 4Q25 net income was R$91 million, down from R$1,125 million in 4Q24.

• Operating cash flow for 2025 was R$13,078 million, up from R$12,204 million in 2024.

• Free cash flow reached R$5,339 million in 2025.

Outlook and guidance

• Positioned to meet growing global protein demand through ongoing investments and capacity expansions.

• Continued focus on expanding processed product sales and international market diversification.

• Ongoing investments in production capacity in the Middle East and China to support global growth.

• Commitment to disciplined capital structure and liquidity management.

• Continued focus on operational efficiency and capturing further synergies.